Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study-Reference-Cited by-同舟云学术

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study

Published:2021-05 Issue:10 Volume:10 Page:3165-3176
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Zhang Rui¹²,Wang Lili¹,Chen Peng³,Gao Xiaoning¹^ORCID,Wang Shuhong¹,Li Fei¹,Dou Liping¹,Gao Chunji¹,Li Yan¹⁴,Liu Daihong¹^ORCID

Affiliation:

1. Department of Hematology Chinese PLA General Hospital Beijing China

2. Department of Hematology People's Hospital of Cangzhou Hebei China

3. Department of Hematology the 7th Medical Center of Chinese PLA General Hospital Beijing China

4. Department of Hematology Peking University Third Hospital Beijing China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3763

Reference53 articles.

1. Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms

2. Genomic Classification and Prognosis in Acute Myeloid Leukemia

3. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

4. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases

5. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications;Cancers;2024-09-03

2. Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34+ and CD3+ donor chimerism (DC) monitoring;Leukemia Research;2024-07

3. The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation;Frontiers in Immunology;2024-04-11

4. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect;Frontiers in Immunology;2024-03-20

5. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches;Annals of Hematology;2023-09-28